JP2006501292A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501292A5
JP2006501292A5 JP2004540927A JP2004540927A JP2006501292A5 JP 2006501292 A5 JP2006501292 A5 JP 2006501292A5 JP 2004540927 A JP2004540927 A JP 2004540927A JP 2004540927 A JP2004540927 A JP 2004540927A JP 2006501292 A5 JP2006501292 A5 JP 2006501292A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
substituents
cor
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004540927A
Other languages
English (en)
Japanese (ja)
Other versions
JP4653485B2 (ja
JP2006501292A (ja
Filing date
Publication date
Priority claimed from GBGB0223039.9A external-priority patent/GB0223039D0/en
Application filed filed Critical
Publication of JP2006501292A publication Critical patent/JP2006501292A/ja
Publication of JP2006501292A5 publication Critical patent/JP2006501292A5/ja
Application granted granted Critical
Publication of JP4653485B2 publication Critical patent/JP4653485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004540927A 2002-10-04 2003-09-25 ガンマ−セクレターゼインヒビターとしてのシクロヘキシルスルホン誘導体 Expired - Fee Related JP4653485B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223039.9A GB0223039D0 (en) 2002-10-04 2002-10-04 Therapeutic compounds
PCT/GB2003/004102 WO2004031137A1 (en) 2002-10-04 2003-09-25 Cyclohexyl sulphone derivatives as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2006501292A JP2006501292A (ja) 2006-01-12
JP2006501292A5 true JP2006501292A5 (enExample) 2010-03-18
JP4653485B2 JP4653485B2 (ja) 2011-03-16

Family

ID=9945313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540927A Expired - Fee Related JP4653485B2 (ja) 2002-10-04 2003-09-25 ガンマ−セクレターゼインヒビターとしてのシクロヘキシルスルホン誘導体

Country Status (10)

Country Link
US (1) US7101895B2 (enExample)
EP (1) EP1551797B1 (enExample)
JP (1) JP4653485B2 (enExample)
AT (1) ATE354562T1 (enExample)
AU (1) AU2003267614B2 (enExample)
CA (1) CA2500964C (enExample)
DE (1) DE60312016T2 (enExample)
ES (1) ES2280774T3 (enExample)
GB (1) GB0223039D0 (enExample)
WO (1) WO2004031137A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
US7399775B2 (en) 2001-12-27 2008-07-15 Daiichi Pharmaceutical Co., Ltd. β-amyloid protein production/secretion inhibitor
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
AR047666A1 (es) * 2004-02-20 2006-02-01 Merck Sharp & Dohme Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
WO2006123184A2 (en) * 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
GB0513747D0 (en) * 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
AR059075A1 (es) 2006-01-20 2008-03-12 Schering Corp Bencesulfonil - cromano , tiocromano tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2435416B1 (en) * 2007-07-05 2016-03-30 Merck Sharp & Dohme Corp. Tetrahydropyranochromene gamma secretase inhibitors
US8618123B2 (en) * 2007-07-17 2013-12-31 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010060088A2 (en) 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2393776B1 (en) * 2009-02-06 2014-05-14 Merck Sharp & Dohme Corp. Novel trifluoromethylsulfonamide gamma secretase inhibitor
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3092215B1 (en) * 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Cyclohexyl sulfone ror gamma modulators
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3324965A4 (en) 2015-07-24 2019-07-03 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
EP4076459B1 (en) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
CN111205264A (zh) * 2020-02-25 2020-05-29 成都睿智化学研究有限公司 一种合成同位羟基和甲磺酰甲基化合物的新方法
WO2021195362A1 (en) 2020-03-26 2021-09-30 Seagen Inc. Methods of treating multiple myeloma
CN120225528A (zh) 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
KR20250116773A (ko) 2022-12-14 2025-08-01 머크 샤프 앤드 돔 엘엘씨 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802013A (en) 1954-02-12 1957-08-06 Searle & Co 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof
US2812330A (en) 1956-05-02 1957-11-05 Searle & Co Sulfone derivatives of 2, 6-piperidinedione
JPS5625149A (en) 1979-08-08 1981-03-10 Sagami Chem Res Center Keto ester derivative and its preparation
JPS5626847A (en) 1979-08-13 1981-03-16 Sagami Chem Res Center Preparation of substituted salicylic acid derivative
JPS5626866A (en) 1979-08-13 1981-03-16 Sagami Chem Res Center Unsaturated ketoester derivative and its preparation
CA2191924A1 (en) * 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
JP2003528076A (ja) * 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
US7122675B2 (en) * 2001-08-03 2006-10-17 Schering Corporation Gamma secretase inhibitors
JP3711131B2 (ja) 2001-08-21 2005-10-26 メルク シャープ エンド ドーム リミテッド 新規のシクロヘキシルスルホン
US7399775B2 (en) 2001-12-27 2008-07-15 Daiichi Pharmaceutical Co., Ltd. β-amyloid protein production/secretion inhibitor
DE10201392A1 (de) 2002-01-16 2003-07-31 Bayer Ag Phenylsulfoxide und-sulfone
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
JP3092689U (ja) 2002-09-10 2003-03-20 船井電機株式会社 光ピックアップ
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
DE10254875A1 (de) 2002-11-25 2004-06-03 Bayer Healthcare Ag Phenylsulfoxid und -sulfon-Derivate
GB0304524D0 (en) 2003-02-27 2003-04-02 Merck Sharp & Dohme Therapeutic agents
KR20060013404A (ko) 2003-05-16 2006-02-09 머크 샤프 앤드 돔 리미티드 γ-세크레타제 억제용 사이클릭 설폰아미드
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
GB0323258D0 (en) 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds

Similar Documents

Publication Publication Date Title
JP2023539463A5 (enExample)
JP2007508359A5 (enExample)
JP2005508905A5 (enExample)
JP2009515872A5 (enExample)
JP2004504348A5 (enExample)
JP2004501905A5 (enExample)
JP2002526516A5 (enExample)
JP2003503387A5 (enExample)
JP2004527498A5 (enExample)
JP2006521359A5 (enExample)
RU2444362C2 (ru) Лекарственное средство
JP2002501945A5 (enExample)
CA2500964A1 (en) Cyclohexyl sulphone derivatives as gamma-secretase inhibitors
JP2007528417A5 (enExample)
JP2008133278A5 (enExample)
JP2007511546A5 (enExample)
JP2004532266A5 (enExample)
JP2001526258A5 (enExample)
JP2006515858A5 (enExample)
JP2004525117A5 (enExample)
JP2004506736A5 (enExample)
JP2004521124A5 (enExample)
JP2010540525A5 (enExample)
JP2009529540A5 (enExample)
JP2009534404A5 (enExample)